Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries.
Brigitte MichelsenStylianos GeorgiadisDaniela Di GiuseppeAnne G LoftMichael J NissenFlorenzo IannoneManuel Pombo-SuarezHerman MannZiga RotarKari K EklundTore K KvienMaria Jose SantosBjorn GudbjornssonCatalin CodreanuSema YilmazJohan Karlsson WallmanCecilie H BraheBurkhard MöllerEnnio G FavalliCarlos Sánchez-PiedraLucie NekvindovaMatija TomsicNina TrokovicEirik K KristianslundHelena SantosThorvardur J LöveRuxandra IonescuYavuz PehlivanGareth T JonesIrene van der Horst-BruinsmaLykke M ØrnbjergMikkel ØstergaardMerete L HetlandPublished in: Arthritis care & research (2021)
In this large real-world study on secukinumab treatment in PsA, 6- and 12-month effectiveness was comparable to previous observational studies of TNFi. Retention, remission, LDA and response rates were significantly better for b/tsDMARD naïve patients, independent of time since diagnosis and varied significantly across the European countries.